The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | A | Alimentary tract and metabolism | |
| 2 | A10 | Drugs used in diabetes | |
| 3 | A10B | Blood glucose lowering drugs, excl. insulins | |
| 4 | A10BX | Other blood glucose lowering drugs, excl. insulins | |
| 5 | A10BX16 |
| Active Ingredient | Description | |
|---|---|---|
| Tirzepatide |
Tirzepatide is a long acting dual GIP and GLP-1 receptor agonist. Both receptors are present on the pancreatic α and β endocrine cells, brain, heart, vasculature, immune cells (leukocytes), gut and kidney. GIP receptors are also present on adipocytes. The activity of tirzepatide on the GIP receptor is similar to native GIP hormone. Tirzepatide improves glycaemic control by lowering fasting and postprandial glucose concentrations in patients with type 2 diabetes through several mechanisms. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| MOUNJARO Solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC | |
| ZEPBOUND Solution for injection | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
